Start-ups & Opportunities
Swiss biotech Nouscom raises €120 million for cancer-interception vaccine trial
Basel biotech Nouscom raised €120 million ($135 million) in a Series D on October 19, 2026 to take its NOUS-209 vaccine for Lynch syndrome carriers into a larger trial.
20 Oct 2026, 14:51 IST